Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
Thymalin: Evidence Summary
Evidence summary for Thymalin across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to Thymalin overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Age-related immune decline | Tier D | 1 | Khavinson 2003 prospective cohort; no Western RCTs |
| Immunodeficiency | Tier D | 0 | Uncontrolled Russian clinical reports only |
| Longevity / anti-aging | Tier D | 0 | Long-term follow-up data from Khavinson group; methodological limitations |
References (2)
- Peptide bioregulation of aging: results and prospects — Khavinson VK . Bulletin of Experimental Biology and Medicine (2003) PMID: 19830585
- Thymosin alpha 1: a comprehensive review — Romani L, et al. . Annals of the New York Academy of Sciences (2002) PMID: 38308608